Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury

Table 1

Cell cycle analysis (using Tali image-based cytometer) of NRK-52E cells exposed to 30 mM glucose or osmotic control media with or without epalrestat (1 M) for 48 h.

Treatment groups	Percentage of cells at different stages of cell cycle
	G1	S	G2
Vehicle-treated control	51.5 ± 1.2	27.75 ± 5.5	19.25 ± 3.5
Vehicle-treated high glucose	59 ± 2	27.33 ± 4.7	13 ± 5.6
Vehicle-treated osmotic control	71.5 ± 4.5	23 ± 5	4 ± 0.1
Control + 1 µM epalrestat	49.75 ± 3.7	26 ± 5.9	21.25 ± 5.9
High glucose + 1 µM epalrestat	61.5 ± 3.9	23.5 ± 5.2	14.5 ± 3.1
Osmotic control + 1 µM epalrestat	62.67 ± 4.3	22.33 ± 6.3	15.67 ± 3.9